Table 1 Demographic and morphological features
Age at diagnosis, median (range), years | 61 (31–86) |
|---|---|
Menopause | |
 Yes | 80.8% (126/156) |
 No | 19.2% (30/156) |
Medical comorbidities | |
 Hypertension | 36.5% (57/156) |
 Diabetes | 21.2% (33/156) |
 History of Colorectal cancer | 5.1% (8/156) |
 History of Breast cancer | 3.2% (5/156) |
CA125, median (range), U/ml | 22.1 (5–736.2) |
 Elevated | 31.9% (46/144) |
  Stage I/II | 11.1% (16/144) |
  Stage III/IV | 20.8% (30/144) |
 Normal | 68.1% (98/144) |
FIGO stage | |
 Stage I | 53.2% (83/156) |
 Stage II | 5.8% (9/156) |
 Stage III | 29.5% (46/156) |
 Stage IV | 11.5% (18/156) |
Rate of pathology coincidence | |
 Hysteroscopy | 69.6% (32/87) |
 Non-hysteroscopy | 59.1% (55/87) |
Histology, No. (%) | |
 Pure CCC | 59% (92/156) |
 Mixed CCC | 41% (64/156) |
  CCC + EmC | 52 |
  CCC + EmC + carcinosarcoma | 1 |
  CCC + EmC + SC | 3 |
  CCC + SC | 8 |
LVSI | |
 ( +) | 25% (39/156) |
MI | |
  ≥ 1/2 | 40.6% (63/155) |
PWC | |
 ( +) | 14.9% (20/134) |
Lymph node metastasis | |
 No | 70.2% (99/141) |
 Yes | 29.8% (42/141) |
  PLN ( +) PALN ( −) | 25 |
  PLN ( −) PALN ( +) | 6 |
  PLN ( +) PALN ( +) | 11 |
Adjuvant treatment | 83.3% (130/156) |
 CT | 81 |
 RT | 5 |
 CRT | 44 |
No. of postoperative chemotherapy cycles, median (range) | 5 (1–9) |